Avalo Therapeutics announced a $375 million public offering of common stock and pre-funded warrants priced at $17.75 per share to advance the clinical development of its IL-1β monoclonal antibody treatment, abdakibart. The offering includes 19.73 million shares and 1.4 million pre-funded warrants, with an option for underwriters to buy an additional 3.17 million shares. Proceeds will support Phase 3 trials and general corporate purposes. The offering is expected to close on May 7, 2026, and is managed by several major investment banks.
Sun Communities reported a strong Core Funds from Operations (FFO) of $1.84 per share for Q2 2026, surpassing its guidance range of $1.71 to $1.79. However, the company posted a net loss of $8.08 per diluted share, mainly due to losses from discontin...
T3 Defense's stock soared 201% following its subsidiary's expansion of defense technology into industrial materials, signaling strong growth potential. NextCure saw a 20.75% rise driven by a significant short squeeze, reflecting heavy short interest ...
Environics Analytics has named Cenker Ozhelvaci as Head of Sales for its core direct sales teams. Ozhelvaci brings extensive experience from sectors like financial services and technology, having previously led sales at Provenir and Amazon Canada. Hi...
AT&T reported better-than-expected earnings and announced a $10 billion share buyback program. Despite the positive results and buyback plan, the stock still trades at a relatively low valuation of 8 times earnings and offers a 4.6% dividend yield. T...
AstraZeneca reported a 21% increase in core earnings per share to $2.63 for Q2 2026, surpassing analyst expectations of $2.50. Total revenue rose 6% to $15.38 billion, driven by strong sales in oncology and rare disease drugs, offsetting pressure fro...
